1. Home
  2. RDN vs BLCO Comparison

RDN vs BLCO Comparison

Compare RDN & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Radian Group Inc.

RDN

Radian Group Inc.

HOLD

Current Price

$35.94

Market Cap

5.0B

Sector

Finance

ML Signal

HOLD

Logo Bausch + Lomb Corporation

BLCO

Bausch + Lomb Corporation

HOLD

Current Price

$15.80

Market Cap

5.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RDN
BLCO
Founded
1977
1853
Country
United States
Canada
Employees
N/A
N/A
Industry
Property-Casualty Insurers
Ophthalmic Goods
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.0B
5.9B
IPO Year
2008
2022

Fundamental Metrics

Financial Performance
Metric
RDN
BLCO
Price
$35.94
$15.80
Analyst Decision
Buy
Buy
Analyst Count
6
11
Target Price
$40.67
$18.45
AVG Volume (30 Days)
1.1M
469.3K
Earning Date
05-06-2026
04-29-2026
Dividend Yield
2.73%
N/A
EPS Growth
5.61
N/A
EPS
0.89
N/A
Revenue
$1,197,084,000.00
$5,101,000,000.00
Revenue This Year
N/A
$8.65
Revenue Next Year
$2.66
$5.59
P/E Ratio
$40.88
N/A
Revenue Growth
N/A
6.47
52 Week Low
$31.50
$11.22
52 Week High
$38.84
$18.92

Technical Indicators

Market Signals
Indicator
RDN
BLCO
Relative Strength Index (RSI) 47.03 42.13
Support Level $34.39 $15.67
Resistance Level $37.30 $16.41
Average True Range (ATR) 1.05 0.38
MACD -0.18 -0.00
Stochastic Oscillator 27.00 18.00

Price Performance

Historical Comparison
RDN
BLCO

About RDN Radian Group Inc.

Radian Group Inc is engaged in mortgage and real estate services. It provides both credit-related mortgage insurance coverage and other products and services across the residential real estate and mortgage finance industries. It has one reportable segment, Mortgage Insurance, which primarily derives its revenue by providing private mortgage insurance on residential first-lien mortgage loans to mortgage lending institutions and mortgage credit investors.

About BLCO Bausch + Lomb Corporation

Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.

Share on Social Networks: